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Introduction  and  Objectives:  Cardiovascular  disease  is  the  leading  cause  of  death  in  Portugal
and atherosclerosis  is  the  most  common  underlying  pathophysiological  process.  The  aim  of
this study  was  to  quantify  the  economic  impact  of  atherosclerosis  in  Portugal  by  estimating
disease-related  costs.
Methods:  Costs  were  estimated  based  on  a  prevalence  approach  and  following  a  societal  per-
spective. Three  national  epidemiological  sources  were  used  to  estimate  the  prevalence  of  the
main clinical  manifestations  of  atherosclerosis.  The  annual  costs  of  atherosclerosis  included
both direct  costs  (resource  consumption)  and  indirect  costs  (impact  on  population  productiv-
ity). These  costs  were  estimated  for  2016,  based  on  data  from  the  Hospital  Morbidity  Database,
the health  care  database  (SIARS)  of  the  Regional  Health  Administration  of  Lisbon  and  Tagus
Valley including  real-world  data  from  primary  care,  the  2014  National  Health  Interview  Survey,
and expert  opinion.
Results:  The  total  cost  of  atherosclerosis  in  2016  reached  1.9  billion  euros  (58%  and  42%  of
which was  direct  and  indirect  costs,  respectively).  Most  of  the  direct  costs  were  associated
with primary  care  (55%),  followed  by  hospital  outpatient  care  (27%)  and  hospitalizations  (18%).
Indirect costs  were  mainly  driven  by  early  exit  from  the  labor  force  (91%).
Conclusions:  Atherosclerosis  has  a  major  economic  impact,  being  responsible  for  health  expen-
diture equivalent  to  1%  of  Portuguese  gross  domestic  product  and  11%  of  current  health
expenditure  in  2016.
©  2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
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Os  custos  da  aterosclerose  em  Portugal
Resumo
Introdução  e  objetivos:  As  doenças  cardiovasculares  são  a  principal  causa  de  morte  em  Portu-
gal, sendo  a  aterosclerose  o  processo  fisiopatológico  subjacente  mais  comum.  O  objetivo  deste
estudo foi  quantificar  o  impacto  económico  da  aterosclerose  em  Portugal  através  da  estimação
dos custos  associados.
Métodos:  A  estimativa  dos  custos  foi  realizada  na  ótica  da  prevalência  e  na  perspetiva  da
sociedade.  A  prevalência  das  principais  manifestações  focais  da  aterosclerose  foi  estimada
com recurso  a  três  fontes  epidemiológicas  nacionais.  O  custo  anual  da  aterosclerose  incluiu
custos diretos  (consumos  de  recursos)  e  indiretos  (impacto  na  produtividade  da  população).
Estes custos  foram  estimados  para  o  ano  de  2016  com  base  nos  dados  da  Base  de  Dados  de
Morbilidade  Hospitalar,  do  Sistema  de  Informação  da  Administração  Regional  de  Saúde  de  Lisboa
e Vale  do  Tejo  que  integra  informação  da  prática  clínica  real  em  ambiente  de  cuidados  de  saúde
primários,  do  Inquérito  Nacional  de  Saúde  de  2014  e  na  opinião  de  Peritos.
Resultados:  O  custo  da  aterosclerose  em  2016  totalizou  cerca  de  1,9  mil  milhões  de  euros  (58%
e 42%  correspondendo  a  custos  diretos  e  indiretos,  respetivamente).  A  maior  parte  dos  custos
diretos esteve  associada  aos  cuidados  de  saúde  primários  (55%),  seguindo-se  o  ambulatório
hospitalar  (27%)  e,  por  último,  os  episódios  de  internamento  (18%).  Os  custos  indiretos  foram
principalmente  determinados  pela  não  participação  no  mercado  de  trabalho  (91%).
Conclusões:  A  aterosclerose  apresenta  um  importante  impacto  económico,  correspondendo  a
uma despesa  equivalente  a  1%  do  Produto  Interno  Bruto  nacional  e  a  11%  da  despesa  corrente
em saúde,  em  2016.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é  um
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therosclerosis  is  a  disease  of  the  elastic  arteries  (large  and
edium  caliber)  and  the  muscular  arteries  that  is  anato-
opathologically  characterized  by  plate-shaped  lesions
nown  as  atheromas  or  plaques.1 Depending  on  the  arterial
erritory  involved  it  can  have  different  clinical  manifesta-
ions,  of  which  the  best-known  are  ischemic  heart  disease
IHD),  ischemic  cerebrovascular  disease  (CVD),  and  periph-
ral  arterial  disease  (PAD).1 These  manifestations  are  part
f  the  group  that  make  up  cardiovascular  disease,  which
emains  the  leading  cause  of  death  worldwide,2 in  Europe3
nd  in  Portugal  (27%  of  all  deaths  in  20174).  In  addition
o  the  high  mortality  related  to  atherosclerosis,  it  is  also
ssociated  with  significant  morbidity.5 Overall,  therefore,
therosclerosis  has  a  considerable  impact  on  health  at
oth  individual  and  populational  levels,  and  is  expected
o  result  in  economic  consequences  due  to  the  associated
esource  consumption,  not  only  for  treatment  of  established
therosclerosis,  but  also  for  disease  prevention.
The  aim  of  this  study  was  to  estimate  the  costs  of
therosclerosis  in  mainland  Portugal,  in  order  to  quantify
ts  economic  impact  from  the  standpoint  of  the  country’s
ational  Health  Service.
ethods
he  study  population  consisted  of  the  resident  population
f  mainland  Portugal  aged  ≥18  years.  Costs  were  estimated
ased  on  a  prevalence  approach,  i.e.  costs  associated  specif-
cally  with  atherosclerosis  during  2016  (the  most  recent  year
or  which  data  were  available  at  the  time  of  the  study).  A
ocietal  perspective  was  adopted,  which  considered  direct
osts  (resource  consumption)  and  indirect  costs  (impact  on
opulation  productivity)  associated  with  the  disease.  The
anifestations  of  atherosclerosis  -- IHD  (myocardial  infarc-
ion  [MI],  chronic  coronary  artery  disease  [CAD]  and  ischemic
eart  failure  [HF]),  ischemic  CVD  (ischemic  stroke),  and  PAD
-  were  analyzed  separately  since  they  have  different  eco-
omic  and  social  impacts.
revalence
he  prevalence  of  the  clinical  manifestations  of  atheroscle-
osis  was  estimated  on  the  basis  of  data  from  the  2014
ational  Health  Interview  Survey6 carried  out  by  the
ational  Health  Institute  Doutor  Ricardo  Jorge  (INSA),  an
bservational  study  by  Menezes  et  al.,7 and  the  EPICA
Epidemiologia  da  Insuficiência  Cardíaca  e  Aprendizagem)
tudy.8
Affirmative  answers  in  the  National  Health  Survey  to  the
uestion  whether  the  respondent  had  had  any  of  the  fol-
owing  conditions  in  the  previous  12  months  --  ‘‘myocardial
nfarction  (heart  attack)  or  chronic  consequences  of  myocar-
ial  infarction’’,  ‘‘coronary  disease  or  angina’’,  or  ‘‘stroke
r  chronic  consequences  of  stroke’’  --  were  used  to  estimate
he  self-reported  prevalence  of  MI,  chronic  CAD  and  stroke,
espectively.6 The  prevalence  of  ischemic  stroke  was  esti-
ated  assuming  that  83%  of  cases  of  stroke  are  ischemic  in
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al  Morbidity  Database  (BDMH)  of  the  Central  Administration
f  the  National  Health  System  (ACSS)  for  2016.12
The  study  by  Menezes  et  al.7 was  used  to  calculate  the
revalence  of  PAD  and  the  proportion  of  symptomatic  cases.
he  study  aimed  to  determine  the  prevalence  of  PAD  in
he  Portuguese  population  and  to  assess  its  relationship
ith  demographic  and  anthropometric  characteristics,  risk
actors  and  symptoms.  Information  was  collected  via  a  ques-
ionnaire  applied  to  a  total  of  5731  individuals  aged  over
0  years  in  mainland  Portugal.  The  diagnosis  of  PAD  was
btained  by  measuring  the  ankle-brachial  index.7
The  prevalence  of  ischemic  HF  was  estimated  using  data
rom  the  EPICA  study  on  individuals  with  HF  and  suspected
oronary  disease.8 A  conservative  approach  was  adopted  in
hich  only  New  York  Heart  Association  (NYHA)  functional
lasses  II-IV  were  included,  the  same  criterion  as  that  used
y  the  authors  of  the  present  study  for  estimating  the  costs
nd  disease  burden  of  HF  in  Portugal.9,10
The  prevalence  of  each  of  the  clinical  manifestations  of
therosclerosis  in  2016  was  estimated  by  applying  the  preva-
ences  (by  demographic  cell)  obtained  from  the  original
ources  cited  above  to  the  population  of  mainland  Portugal
n  that  year.11
irect  costs
he  direct  costs  analyzed  in  this  study  included  medical
osts  (costs  of  hospitalizations  and  outpatient  care,  includ-
ng  those  arising  from  hospital  outpatient  care  and  primary
ealth  care  [PHC]),  and  non-medical  costs,  particularly
hose  related  to  transportation.
ospitalization  costs
onsumption  of  resources  due  to  hospitalizations  for
therosclerotic  diseases  was  estimated  based  on  data  from
he  BDMH  hospital  morbidity  database  for  2016.12
Episodes  of  hospitalization  in  the  BDMH  were  identified
sing  the  ninth  (ICD-9-CM)  and  tenth  (ICD-10-CM)  revisions
f  the  International  Classification  of  Diseases,  Clinical  Mod-
fication.  All  episodes  with  a  principal  diagnosis  of  ICD-9-CM
nd  ICD-10-CM  codes  under  ‘‘Ischemic  heart  diseases’’  and
‘Cerebrovascular  diseases’’  of  ischemic  etiology  were  con-
idered  to  be  IHD  (MI  and  chronic  CAD)  and  ischemic  CVD,
espectively.  Cases  of  PAD  were  identified  by  means  of  the
CD-9-CM  codes  published  by  Agarwal  et  al.13 and  the  Global
urden  of  Disease  Study  2015.14 Supplementary  Table  S1  lists
he  ICD-9-CM  and  ICD-10-CM  codes  used  to  identify  hospital-
zations.
The  costs  of  hospitalizations  arising  from  IHD,  ischemic
VD  and  PAD  were  calculated  as  the  sum  of  the  costs  of
pisodes  identified  by  the  BDMH  microdata.  For  each  episode
he  price  used  was  that  set  out  in  Order  in  Council  no.
34/2015,  and  thus  reflects  the  different  rules  used  for  cal-
ulating  these  prices,  including  the  severity  of  the  episode.
For  ischemic  HF,  the  cost  of  hospitalization  for  HF  previ-
usly  estimated  by  the  authors  was  applied  in  proportion  to
he  prevalence  of  ischemic  HF  in  NYHA  classes  II--IV,  which,
ccording  to  the  EPICA  study,  is  36%.8 The  cost  of  ischemic
F  hospitalization  for  episodes  identified  with  the  ‘‘Cardiac
ransplantation’’  procedure  code  included  funds  attributed
o  public  or  private  entities  authorized  to  perform  collection
1
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nd  transplantation  under  Order  no.  7215/2015  (D  18  018.62
er  episode).
ospital  outpatient  costs
he  BDMH  was  also  used  to  identify  hospital  outpatient
pisodes  coded  by  Diagnosis-Related  Group  (DRG),  using
he  relevant  ICD-9-CM  and  ICD-10-CM  codes  (Supplementary
able  S1).  The  costs  of  these  episodes  were  calculated  using
he  same  method  as  for  hospitalizations.
Consumption  of  other  resources  (medical  and  non-
edical)  in  the  hospital  outpatient  setting  that  are  not
ssociated  with  a  DRG  code  and  are  therefore  not  found
n  the  BDMH  was  estimated  by  elicitation  from  an  expert
anel.  The  eleven  experts,  selected  to  represent  the  coun-
ry’s  different  regions,  responded  independently  to  specific
uestions  via  an  emailed  questionnaire  on  patterns  of
onsumption  of  medical  care  nationwide  (consultations,
omplementary  diagnostic  and  therapeutic  procedures
ncluding  physical  medicine  and  rehabilitation,  support
roducts,  and  social  responses).  Their  responses  were  ana-
yzed  and  simple  means  of  the  values  were  calculated,
xcluding  outliers  by  using  trimmed  means,  a  necessary  pre-
aution  when  some  values  are  very  far  from  others.
The  mean  resource  consumption  by  a  patient  undergoing
ospital  outpatient  care  could  thus  be  calculated.  On  the
asis  of  these  figures,  the  number  of  urgent  (transportation
or  emergency  departments  [EDs])  and  non-urgent  (trans-
ortation  for  medical  consultations)  journeys  required  in
his  setting  could  be  estimated.
Health  resources  were  valued  according  to  the  prices  set
y  Orders  in  Council  nos.  254/2018  and  353/2017.  The  costs
f  patient  transportation  were  those  published  by  NOVA
ealthcare  Initiative  Research  for  expenditure  on  trans-
ortation  by  the  patient  when  going  to  the  hospital.15 The
otal  cost  of  each  atherosclerosis  manifestation  was  cal-
ulated  as  the  mean  cost  per  patient  multiplied  by  the
revalence  of  each  disease,  taking  into  account  the  propor-
ion  of  patients  who  received  hospital  outpatient  care  as  set
y  the  expert  panel.
utpatient  costs  in  primary  health  care
 cross-sectional  study  was  performed  to  estimate  resource
onsumption  in  PHC,  by  consulting  the  health  care  database
SIARS)  of  the  Regional  Health  Administration  of  Lisbon  and
agus  Valley  (ARSLVT).16 SIARS  functions  as  a  repository  of
dministrative,  clinical  and  demographic  data  on  users  of
he  health  centers  of  a  specific  region.  In  2016,  the  ARSLVT
IARS  recorded  data  on  1  879  705  users  aged  18  years  or
ver.  Supplementary  Table  S2  presents  the  selection  crite-
ia  used  to  identify  the  subpopulation  to  be  analyzed  with
egard  to  resource  consumption  related  to  atherosclerosis.
his  analysis  was  used  to  determine  the  number  of  consul-
ations  and  diagnostic  and  therapeutic  procedures  relevant
o  cardiovascular  disease  (excluding  physical  medicine  and
ehabilitation)  and  to  directly  calculate  the  costs  of  medi-
ation  consumed  in  the  outpatient  setting  by  patients  with
therosclerosis  and  charged  to  the  ARSLVT  with  atheroscle-
osis  irrespective  of  where  they  were  prescribed  (PHC,
ospital  outpatient  clinics  or  private  facilities).  It  was
ssumed  that  these  data  reflected  the  consumption  of  med-
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etting.  However,  this  is  a  conservative  approach,  since  it
oes  not  consider  medication  consumed  by  patients  followed
nly  in  the  hospital  outpatient  setting.  The  data  from  SIARS
ere  also  used  to  estimate  the  number  of  non-urgent  jour-
eys  (transportation  for  medical  consultations)  required  by
atients  followed  in  PHC.  The  costs  calculated  for  PHC  in  the
RSLVT  were  extrapolated  to  mainland  Portugal  by  multiply-
ng  them  by  2.6  (the  ratio  of  all  adults  resident  in  mainland
ortugal  in  2016  to  the  number  registered  in  the  ARSLVT).
Unit  costs  were  based  on  previously  used  sources  to  calcu-
ate  resource  consumption  in  the  hospital  outpatient  setting.
upplementary  Tables  S3--S8  show  all  the  unit  costs  used  in
his  study.
ndirect  costs
he  only  indirect  costs  considered  in  this  study  were  those
ssociated  with  productivity  loss  due  to  disease,  exclud-
ng  loss  due  to  premature  death.  Estimates  of  productivity
osses  were  obtained  by  calculating  how  the  major  clini-
al  manifestations  of  atherosclerosis  affect  absenteeism  of
mployed  patients  and  non-participation  in  the  labor  market
ue,  for  example,  to  early  exit  from  the  labor  force  because
f  long-term  disability.
Absenteeism  and  non-participation  in  the  labor  market
ue  to  MI,  chronic  CAD  or  stroke  were  estimated  on  the
asis  of  the  microdata  from  the  2014  National  Health  Sur-
ey.  Absenteeism  was  estimated  by  calculating  employment
ates  in  the  population  aged  under  65  years  with  MI  (39.2%  of
en  and  15.9%  of  women),  with  chronic  CAD  (53.8%  of  men
nd  35.3%  of  women)  and  with  stroke  (40.5%  of  men  and
3.9%  of  women).  In  order  to  assess  non-participation  in  the
abor  market,  the  impact  of  these  diseases  was  estimated  by
easuring  the  difference  between  the  employment  rates  of
ndividuals  aged  under  65  years  with  a  self-reported  history
f  MI,  chronic  CAD  or  stroke  and  the  employment  rates  of
hose  without  such  a  history,  with  the  same  gender  and  age-
roup  distribution.  The  difference  was  estimated  at  21%  in
en  and  35%  in  women  for  MI,  7%  in  men  and  20%  in  women
or  chronic  CAD,  and  23%  in  men  and  19%  in  women  for  stroke
considered  to  be  ischemic  in  nature).
HF  and  PAD  were  not  among  the  self-reported  diseases
n  the  National  Health  Survey.  Each  of  the  three  NYHA
unctional  classes  (II,  III  and  IV)  was  therefore  considered
eparately,  with  patients  aged  between  25  and  65  years
eing  distributed  by  these  classes  in  accordance  with  the
PICA  study.  No  patients  aged  between  25  and  65  years  were
dentified  as  being  in  NYHA  class  IV,  and  so  no  patients  in
his  class  were  included  in  the  estimates  of  indirect  costs.
egarding  the  22%  of  patients  with  NYHA  class  III  ischemic
F,  it  was  assumed  that  their  non-participation  in  the  labor
arket  and  employment  rate  as  an  indicator  of  absenteeism
ould  be  similar  to  those  with  a  history  of  MI.  For  the  71%
f  patients  with  NYHA  class  II  ischemic  HF  a  conservative
pproach  was  taken  by  assuming  that  in  this  group  there
as  no  difference  in  participation  in  the  labor  market  com-
ared  to  the  general  population  (76.0%  in  men  and  69.9%  in
omen).  Employment  rates  for  the  general  population  were
btained  from  Statistics  Portugal  (INE)  for  the  third  quar-









Table  1  Estimated  prevalence  of  ischemic  heart  disease,  stroke  and  peripheral  arterial  disease  in  mainland  Portugal  in  2016.
MI  Chronic  CAD  Ischemic  HF  Stroke  PAD
INS  20146 151  678a 375  278a NR  164  829b NR
Menezes et  al.7 NR  NR  NR  --  248  093c
EPICA  study8 NR  NR  91  046d NR  NR
CAD: coronary artery disease; IHD: ischemic heart disease; INS: National Health Survey; MI: myocardial infarction; NR: not reported; PAD: peripheral arterial disease.
a In total, 449 084 individuals self-reported IHD (MI or chronic CAD).
b Includes ischemic and hemorrhagic stroke. It was assumed that 83% of these strokes were ischemic, in accordance with the distribution in the Hospital Morbidity Database.
c In the present study only symptomatic cases (62%) were considered.
d Includes only New York Heart Association functional classes II--IV.
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dopted,  that  there  was  no  difference  in  participation  in  the
abor  market  compared  to  the  general  population.
Two  reasons  for  absenteeism  were  considered:  absence
rom  work  due  to  consultations,  diagnostic  and  therapeutic
rocedures  and  ED  visits  without  admission;  and  absence  due
o  hospitalization  and  convalescence.  It  was  assumed  that
or  every  consultation  (in  whatever  specialty),  diagnostic
nd  therapeutic  procedure  and  ED  visit  without  admission,
he  patient  lost  a  half,  a  quarter,  or  an  entire  day  of  work,
espectively.  For  time  lost  due  to  hospitalization  and  conva-
escence,  the  time  lost  for  convalescence  was  considered  to
e  equal  to  the  length  of  hospital  stay.
The  monetary  value  of  this  productivity  loss  was  calcu-
ated  according  to  human  capital  theory,18 using  the  mean
roductivity  of  workers  estimated  from  employers’  charges.
he  mean  annual  earnings  in  mainland  Portugal  were  calcu-
ated  as  the  mean  monthly  salary  published  by  the  Office
f  Strategy  and  Planning  of  the  Ministry  of  Labor,  Solidar-
ty  and  Social  Security  (D  1266.3  for  men  and  D  1011.2  for
omen),19 plus  employers’  social  security  contributions  at
 rate  of  23.75%,  and  multiplied  by  14  to  include  holi-
ay  and  Christmas  bonuses.  Daily  productivity  lost  through
bsenteeism  due  to  medical  consultations  and  exams  was
alculated  by  dividing  the  mean  annual  salary  by  230  (the
umber  of  working  days  per  year,  since  consultations  and
xams  only  take  place  on  these  days).  Only  ED  visits  occur-
ing  during  working  hours  were  considered;  these  were
ssumed  to  represent  50%  of  all  ED  episodes  based  on
ational  figures  for  ED  visits  for  all  causes.20 For  absen-
eeism  related  to  hospitalization  and  convalescence,  the
ean  annual  salary  was  divided  by  365  (since  hospitalization
nd  convalescence  can  occur  on  any  day  of  the  week).
Supplementary  Table  S9  summarizes  the  information  used
o  calculate  indirect  costs  related  to  productivity  loss  due
o  absenteeism  in  patients  with  atherosclerosis.
esults
revalence
able  1  presents  the  estimated  prevalence  of  the  differ-
nt  clinical  manifestations  of  atherosclerosis  for  mainland
ortugal  in  2016  in  accordance  with  the  sources  used.11
The  overall  prevalence  of  symptomatic  atherosclerosis
as  estimated  at  742  709  adults  in  mainland  Portugal.  This
gure  is  lower  than  the  sum  of  the  prevalences  of  the  sepa-
ate  manifestations  of  the  disease,  because  in  some  patients
ore  than  one  form  of  the  disease  coexisted.
irect  costs
ospitalization  and  hospital  outpatient  costs
nalysis  of  the  2016  BDMH,  using  the  codes  listed  in  Supple-
entary  Table  S1,  identified  54  813  hospitalizations  for  IHD,
schemic  CVD  and  PAD,  in  addition  to  12  809  hospitalizations
or  ischemic  HF.9 The  total  cost  of  these  hospitalizations  was 199  471  561  in  2016  (Table  2).
Regarding  hospital  outpatient  costs,  analysis  of  the  2016
DMH  identified  7596  hospital  outpatient  episodes,  to  which
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ated  cost  of  all  these  hospital  outpatient  episodes  in  2016
as  D  9  960  966  (Table  3).
Other  hospital  outpatient  costs  were  estimated  based  on
ealth  care  consumption  patterns  as  defined  by  the  expert
anel  and  corresponding  unit  costs.  They  included  ED  visits
ithout  admission,  diagnostic  and  therapeutic  procedures
uring  hospital  follow-up  (and  not  included  in  the  outpa-
ient  episodes  identified  in  the  BDMH),  such  as  laboratory
ests  and  exams  assessing  cardiac  function,  and  consulta-
ions.  The  cost  of  travel  to  and  from  consultations  was  added
o  this  total.
Consumption  of  medication  and  corresponding  costs  were
stimated  by  direct  consultation  of  SIARS.  These  costs  are
ot  included  under  this  heading  but  under  the  next  (outpa-
ient  costs  in  PHC).
Table  4  presents  the  hospital  outpatient  costs  additional
o  those  calculated  directly  from  the  2016  BDMH.  The  total
ost  of  each  manifestation  of  atherosclerosis  was  estimated
s  the  mean  cost  per  patient  multiplied  by  the  preva-
ence  of  each  manifestation  and  considering  the  proportion
f  patients  treated  in  hospital  outpatient  care,  calculated
s  the  percentage  of  patients  with  hospital  consultations
efined  by  the  expert  panel.  The  higher  mean  costs  of
schemic  CVD  is  due  to  the  extra  cost  of  physical  medicine
nd  rehabilitation  for  this  condition.
In  the  case  of  the  total  cost  of  hospital  outpatient  care
ot  associated  with  a  DRG  code  (D  289  049  959  in  2016;
able  4),  the  figure  is  lower  than  the  sum  of  the  costs  for
ach  manifestation  because  the  same  individual  may  present
ore  than  one  clinical  manifestation  of  atherosclerosis.  The
ost  of  a  patient  with  more  than  one  clinical  manifestation
s  assumed  to  be  the  highest  cost  among  these  different
anifestations.
utpatient  costs  in  primary  health  care
he  cross-sectional  study  of  the  SIARS  data  identified  a
otal  of  318  692  PHC  users  with  atherosclerosis  in  the
RSLVT  in  2016,  corresponding  to  a  total  estimated  cost  of
 210  686  792  in  that  year.  Table  5  summarizes  the  distribu-
ion  of  these  costs  according  to  their  origin  (consultations,
iagnostic  and  therapeutic  procedures,  and  medication),
nd  distinguishes  between  preclinical  and  established  dis-
ase.  The  costs  for  medication  cover  all  consumption  in  an
utpatient  setting,  including  medication  prescribed  in  hos-
ital  outpatient  care.
Considering  the  numbers  of  patients  identified  in  SIARS
ith  preclinical  and  established  disease  (the  latter  being
hose  diagnosed  with  one  of  the  three  main  manifestations
f  atherosclerosis),  a  mean  cost  was  obtained  for  each  of
hese  two  patient  types  (Table  6).  This  cost  was  12.6%  higher
n  patients  with  established  disease.  Among  the  three  main
anifestations,  the  cost  of  IHD  was  the  highest,  mainly  due
o  the  costs  of  medication.
The  total  cost  in  mainland  Portugal  associated  with
esource  consumption  for  atherosclerosis  in  PHC  was
 555  811  214,  to  which  were  added  the  costs  of  travel  to
nd  from  consultations  (D  59  790  304).
The  total  direct  cost  of  atherosclerosis  in  mainland  Por-
ugal  in  2016  was  thus  around  D  1.1  billion.
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Table  2  Hospitalization  costs  (identified  in  the  Hospital  Morbidity  Database,  2016).
No.  of  episodes  Mean  cost  per  episode  Total  costc
IHDa 23  125  D  3009  D  69  574  908
Ischemic HFb 12  809  D  3270  D  41  891  362
Ischemic CVD  24  863  D  2491  D  61  940  359
PAD 6825  D  3819  D  26  064  932
Atherosclerosis  67  622 --  D  199  471  561
Source: Hospital Morbidity Database, 2016 and Order in Council no. 234/2015.
CVD: cerebrovascular disease; HF: heart failure; IHD: ischemic heart disease; PAD: peripheral arterial disease.
a Includes manifestations of IHD except ischemic HF.
b Number of episodes and costs of ischemic HF previously estimated by the authors.9 The cost of hospitalizations identified as ‘‘Heart
transplantation’’ includes funds attributed to public or private entities authorized to perform collection and transplantation under Order
no. 7215/2015 (D 18 018.62 per episode).
c The mean cost per episode is rounded to the nearest unit.
Table  3  Hospital  outpatient  costs  (identified  in  the  Hospital  Morbidity  Database,  2016).
No.  of  episodes Mean  cost  per  episode Total  cost
IHDa 7397  D  1230  D  9  095  144
Ischemic HFb 224  D  1359  D  304  267
Ischemic CVD  6  D  2723  D  16  341
PAD 193  D  2825  D  545  214
Atherosclerosis  7820  --  D  9  960  966
Source: Hospital Morbidity Database, 2016 and Order in Council no. 234/2015.
CVD: cerebrovascular disease; HF: heart failure; IHD: ischemic heart disease; PAD: peripheral arterial disease.
a Includes manifestations of IHD except ischemic HF.
b Number of episodes and costs of ischemic HF previously estimated by the authors.9
Table  4  Hospital  outpatient  costs  (not  associated  with  a  Diagnosis-Related  Group  code).
Prevalence  in  hospital  outpatient  carea Mean  cost  per  patientb Total  cost
MI  101  252  D  320  D  32  433  356
Chronic CAD  159  493  D  220  D  35  052  149
Ischemic HF  40  912  D  556  D  22  754  011
Ischemic CVD  83  239  D  2303  D  191  689  919
PAD 71  666  D  631  D  45  202  787
Total D  289  049  959c
Source: Expert panel and Order in Council no. 254/2018.
CAD: coronary artery disease; CVD: cerebrovascular disease; HF: heart failure; MI: myocardial infarction; PAD: peripheral arterial disease.
a Estimated by the expert panel.
b Includes cost of transportation.














Discussionmanifestation of atherosclerosis. The cost of a patient with more t
these different manifestations.
ndirect  costs
he  indirect  cost  of  atherosclerosis  in  mainland  Portugal  in
016  totaled  D  810  812  882,  of  which  91%  was  due  to  non-
articipation  in  the  labor  market  and  the  other  9%  was
ttributed  to  absenteeism  due  to  consultations,  diagnostic
nd  therapeutic  procedures,  ED  visits  without  admission,
ospitalizations  and  convalescence.  Table  7  details  the
tructure  of  these  indirect  costs.
A
s
41ne clinical manifestation is assumed to be the highest cost among
otal  costs
dding  together  all  the  individual  costs  listed  above  gives
n  estimated  total  cost  of  atherosclerosis  in  2016  of
 1  924  896  887  (Table  8).therosclerosis  is  a  chronic  disease  of  the  arteries  that  has  a
ignificant  social  impact  due  to  the  mortality  and  morbidity
5
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Table  5  Outpatient  costs  in  primary  health  care  (based  on  SIARS  2016).
ARSLVT Total  cost  in
mainland  Portugal
Cost  of  preclinical  diseasea Cost  of  established  diseasea Total




D  9  072  780  D  15  304  659  D  24  377  439  D  64  309  880
Medication D  34  650  644  D  79  136  321  D  113  786  965  D  300  180  264
Total D 66  546  355 D  144  140  618 D  210  686  793 D  555  811  214
ARSLVT: Regional Health Administration of Lisbon and Tagus Valley; SIARS: regional health care database.
a Preclinical disease was defined as the presence of ≥3 risk factors in patients with no recorded diagnosis of manifestations of atheroscle-
rosis and not taking antiplatelet or peripheral arterial disease-spec
accounted for 34% of the patients identified in SIARS.
Table  6  Mean  cost  per  patient  with  atherosclerosis  (based
on SIARS  2016).
Patients  with  clinical  manifestations D  687
IHD D  808
Ischemic  CVD D  695
PAD D  788
Patients  without  clinical  manifestations D  610
Source: Authors’ estimate using data from the 2016 SIARS
database.
CVD: cerebrovascular disease; IHD: ischemic heart disease;

































































ssociated  with  its  clinical  manifestations,  particularly  IHD,
schemic  CVD  and  PAD.  The  aim  of  the  present  study  was  to
stimate  the  costs  of  atherosclerosis  in  mainland  Portugal  in
016  in  order  to  quantify  its  economic  impact  on  the  country.
This  study  was  based  on  the  prevalence  of  symptomatic
therosclerosis  in  mainland  Portugal,  estimated  at  742  709
dults,  around  9%  of  the  population.  This  figure  mainly  rep-
esents  the  clinical  manifestations  of  atherosclerosis  that
ause  symptoms  recognized  by  patients.
The  direct  costs  (58%,  mostly  related  to  outpatient  care)
nd  indirect  costs  (42%,  mostly  related  to  non-participation
n  the  labor  market)  of  atherosclerosis  in  mainland  Portugal
n  2016  amount  to  more  than  D  1.9  billion,  which  is  equiv-
lent  to  1%  of  the  country’s  gross  domestic  product,  11%  of
urrent  health  expenditure,  and  a  mean  annual  cost  of  D  237
o  every  Portuguese  adult.
There  have  been  few  studies  published  on  the  costs  asso-
iated  with  atherosclerosis.  Vlayen  et  al.21 performed  a
tudy  with  similar  methodology  to  ours  to  estimate  the  cost
f  atherosclerotic  cardiovascular  disease  in  Belgium  in  2004.
hey  provided  separate  estimates  for  the  costs  of  prevention
nd  screening,  preclinical  disease,  and  established  disease.
hen  comparing  the  results  of  the  two  studies,  we  only  con-
idered  the  cost  of  established  disease,  since  this  was  the
isease  form  that  was  best  characterized  in  our  study,  and
xcluded  transportation  costs,  since  they  were  not  counted
n  the  Belgian  study.  The  total  cost  of  established  atheroscle-




41ific medication (see Supplementary Table S2). This population
 3782  per  patient.21 The  equivalent  sum  in  Portugal  for
016  was  D  2215,  which  is  41%  less  than  in  the  Belgian  study.
earing  in  mind  inflation  during  the  period  between  the
wo  studies  (12  years)  and  the  purchasing  power  of  the  two
ountries,  the  real  difference  is  even  greater.  Regarding  the
tructure  of  the  costs,  direct  costs  accounted  for  more  in  the
elgian  study  than  in  ours  (62%  and  51%,  respectively).  The
roportions  of  direct  costs  due  to  hospitalizations  and  out-
atient  care  were  similar  (around  50%  each)  in  the  Belgian
tudy,  whereas  in  our  study  the  costs  of  outpatient  care  (76%)
ere  three  times  higher  than  those  of  hospitalizations  (24%),
hich  may  reflect  differences  in  patient  pathways  in  the  two
ountries’  health  systems.  Among  outpatient  costs,  the  costs
f  medication  had  essentially  the  same  weight  in  the  Belgian
nd  Portuguese  studies  (56%  and  55%,  respectively).
Leal  et  al.22 reported  costs  from  a  societal  perspective
f  cardiovascular  disease  in  each  country  of  the  European
nion  (EU)  for  2003.  In  this  study,  the  total  estimated  cost
or  Portugal  was  D  1.8  billion,  less  than  in  the  present
tudy,  which  focused  only  on  atherosclerosis.  In  addition  to
ethodological  differences,  the  time  interval  between  the
wo  studies  most  likely  contributed  to  these  results.  In  the
U  study,  transportation  costs  (around  D  100  million  in  our
tudy)  were  not  considered  but  informal  care  (amounting
o  D  392  million)  was  included,  unlike  in  our  study,  which
eightens  the  difference  between  the  estimates.  Even  so,
he  distribution  of  total  direct  and  indirect  costs,  direct
nd  indirect,  was  similar  in  the  two  studies  (55%  and  45%,
espectively,  in  both),  although  medication  accounted  for
 considerably  higher  proportion  of  direct  costs  in  the  EU
tudy  (52%  vs.  30%  in  the  Portuguese  study).  It  should  also
e  noted  that  the  per  capita  cost  of  cardiovascular  disease,
ne  of  the  main  clinical  manifestations  of  atherosclerosis,
stimated  by  Leal  et  al.  for  Portugal  using  the  purchasing
ower  parity  method,  was  D  25,  half  of  the  mean  figure  for
he  EU  (D  50).
The  costs  of  atherosclerosis  in  the  USA  can  be  found  in  the
020  Update  to  the  annual  report  published  by  the  American
eart  Association.23 This  publication  presents  a  summary  of
he  epidemiology  and  costs  associated  with  heart  disease,
troke  and  cardiovascular  risk  factors.  It  does  not  provide
ata  specifically  on  atherosclerosis  but  on  the  overall  spec-
rum  of  cardiovascular  and  cerebrovascular  disease.  The
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Table  7  Indirect  costs  of  atherosclerosis  in  mainland  Por-
tugal,  2016.




MI  12  691  D  244  820  444
Chronic  CAD  16  514  D  301  803  884
Ischemic  HF  2473  D  47  061  382
Ischemic  stroke 8971  D  176  159  574
PAD -- --
Subtotal  D  738  306  327c




PHC  D  27  766  959




1.7  D  12  041  394
Hospital  outpatient  care  D  36  985  050
MI 1.9  D  1  551  412
Chronic  CAD  2.4  D  4  097  323
Ischemic  HF  2.4  D  1  297  837
Ischemic  stroke  6.7b D  26  838  741
PAD  5.4  D  4  335  368
Hospitalizations  and
convalescence
D  7  754  547
IHD 10.13  D  1  972  462
Ischemic  HF  20.26  D  3  403  248
PAD 29.48  D  2  378  837
Subtotal  D  72  506  556c
Total  indirect  costs D  810  812  882
CAD: coronary artery disease; CVD: cerebrovascular disease; HF:
heart failure; IHD: ischemic heart disease; MI: myocardial infarc-
tion; PAD: peripheral arterial disease; PHC: primary health care.
a Authors’ estimate based on number of consultations, diag-
nostic and therapeutic procedures and hospitalizations.
b In addition to this figure, it was assumed that individuals were
absent from work for six months after a stroke. To avoid double
counting, absenteeism due to hospitalization for ischemic CVD
is not included.













Table  8  Total  costs  due  to  atherosclerosis  in  mainland  Por-
tugal  in  2016.
Cost  Percentage
of  total
Direct  costs D  1  114  084  005 58%
Hospitalizations
(BDMH)





D  9  960  966  1%
Other
consumptiona
D  289  049  959  15%
PHC  D  615  601  519  32%
Indirect  costs  D  810  812  882  42%
Non-participation
in the  labor  market
D  738  306  327  38%
Absenteeism  D  72  506  556  4%
Total  D  1  924  896  887

































ifestation because the same individual may present more than
one clinical manifestation of atherosclerosis.
otal  estimated  cost  of  cardiovascular  disease  and  stroke  in
020  was  US$351.3  billion  (61%  of  which  was  direct  costs  and
9%  indirect  costs  due  to  loss  of  future  productivity  resul-
ing  from  premature  cardiovascular  disease  and  death  by
troke).
Given  the  paucity  of  relevant  studies  and  differences  in
ethodology  and  time,  the  results  of  the  present  study  are
ard  to  compare  with  others  analyzing  the  costs  of  illness
n  Portugal.  Despite  these  difficulties,  it  should  be  noted
hat  members  of  our  group  have  estimated  the  cost  of  HF
D  405  million  in  2014),9 diabetes  (D  959  million  in  2008),24
reast  cancer  (D  309  million  in  2014)25 and  non-small  cell




41a Includes hospital consultations, emergency department visits
without admission, and diagnostic and therapeutic procedures.
osts  of  these  conditions  compared  to  that  of  atherosclerosis
arrant  the  attention  of  the  health  authorities  concerning
he  latter  problem.
This  study  naturally  presents  various  limitations,  first
nd  foremost  related  to  the  availability  of  national  data.
n  the  absence  of  a  single  source  of  information  on  which
o  base  an  estimate  of  the  prevalence  of  atherosclerosis
n  Portugal,  the  authors  had  to  rely  on  different  sources,
ncluding  the  2014  National  Health  Survey,  the  EPICA  study,
he  study  by  Menezes  et  al.,  and  the  BDMH.  The  estimates
erived  from  these  sources  were  not  always  consistent,
nd  so  it  was  necessary  in  each  case  to  select  the  source
hat  we  considered  best  represented  the  situation  in  the
ountry.  Aware  of  the  risk  of  bias  that  such  a  selection
ould  entail,  we  have  aimed  to  explain  the  reasons  for  our
hoices  when  estimating  the  prevalence  of  each  of  the  clin-
cal  manifestations  of  atherosclerosis.  We  also  decided  to
dopt  a conservative  approach  in  all  cases.  For  example,
here  are  sources  other  than  the  National  Health  Survey
hat  provide  national  data  on  IHD  and  stroke,  particularly
he  VALSIM  study,  a  national  cross-sectional  observational
tudy  that  ran  from  2006  to  2007  and  included  719  general
ractitioners  who  assessed  16  856  patients.  The  study  col-
ected  information  on  previous  diagnoses  of  IHD  (referred
o  as  coronary  disease)  and  stroke  (without  distinguishing
etween  ischemic  and  hemorrhagic  forms).27,28 The  VALSIM
tudy  was  older  than  the  2014  National  Health  Survey  and
lso  obtained  higher  prevalences  of  IHD  and  stroke  (12%  and
5%  higher,  respectively).  In  view  of  this,  and  notwithstand-
ng  the  known  limitations  of  self-reporting,  we  opted  to  use
he  2014  National  Health  Survey  as  the  main  source  of  infor-
ation  on  the  prevalence  of  IHD  (MI  and  chronic  CAD)  and
troke.
Given  the  systemic  nature  of  the  disease,  it  is  not
ncommon  for  more  than  one  clinical  manifestation  of
therosclerosis  to  coexist  in  the  same  patient,  and  it  was
herefore  necessary  to  adjust  the  overall  prevalence  to
7
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ccount  for  this  overlap.  Data  from  SIARS,  particularly
he  clinical  characteristics  of  patients  with  atherosclerosis
reated  in  PHC  in  the  ARSLVT,  were  used  for  this  purpose.
owever,  this  could  not  be  done  in  the  specific  case  of
hronic  CAD,  since  the  proportion  of  cases  recorded  in  the
atabase  was  lower  than  the  national  estimate  based  on
he  National  Health  Survey,  and  so  we  had  to  treat  chronic
AD  as  independent  of  the  other  clinical  manifestations
f  atherosclerosis.  The  assumption  of  independence  is  the
ethod  most  often  used  in  the  literature,  even  for  diseases
n  which  independence  of  the  probability  of  disease  is  clini-
ally  implausible.2
Furthermore,  although  real-life  data  were  used  for  out-
atient  resource  consumption  in  PHC,  these  may  not  be
epresentative  of  the  country  as  a  whole,  since  we  were
ble  to  consult  the  SIARS  of  only  one  of  Portugal’s  five
egional  Health  Administrations,  that  of  Lisbon  and  Tagus
alley.
Another  limitation  of  the  study  is  the  lack  of  a  database
f  hospital  outpatient  information,  particularly  on  care  that
oes  not  generate  DRG  codes.  This  gap  was  filled  by  input
rom  the  expert  panel.  Although  the  members  of  the  panel
ere  varied  intheir  regional  locations  and  medical  spe-
ialties,  their  opinions  may  not  fully  represent  nationwide
linical  practice.
onclusion
he  results  of  this  study  demonstrate  the  importance  of
therosclerosis  at  a  national  level.  In  terms  of  its  economic
mpact  in  mainland  Portugal,  the  cost  of  atherosclerosis  rep-
esented  1%  of  gross  national  product  and  11%  of  current
ealth  expenditure  in  2016.
onflict of interest
his  study  was  funded  by  an  unrestricted  grant  from  Bayer
ortugal,  SA.  Funding  was  independent  of  the  study  out-
omes,  which  are  the  sole  responsibility  of  the  authors.
.A.S.  received  personal  fees,  grants  and  non-financial
upport  for  consulting  services  and  lectures  from  Bayer
ortugal,  Ferrer  and  Bial.  F.A.  received  personal  fees  and
rants  for  consulting  services,  lectures  and  research  from
straZeneca,  Bayer,  Bial,  Daiichi  Sankyo,  Ferrer,  Jaba  Recor-
ati  and  Merck  Sharp  &  Dhome.  D.C.  received  personal  fees,
rants  and  non-financial  support  for  participating  in  scien-
ific  meetings  from  Bristol  Myers  Squibb,  Bayer,  Boehringer
ngelheim,  Daiichi  Sankyo,  Merck  Serono,  Ferrer,  Pfizer,
ovartis  and  Roche.  C.G.  received  personal  fees  for  consult-
ng  services  and  lectures  from  Amgen,  AstraZeneca,  Bayer
nd  Merck  Sharp  &  Dhome.  V.G.  received  personal  fees,
rants  and  non-financial  support  from  Bayer,  AstraZeneca,
aiichi  Sankyo,  Amgen,  Novartis  and  Boehringer  Ingelheim.
.M.S.  received  personal  fees,  grants  and  non-financial
upport  for  consulting  services,  lectures/scientific  meet-
ngs  participation  and  research  from  Amgen,  Bayer,  Daiichi
ankyo,  Jaba  Recordati,  Menarini,  Mylan,  Novartis  and
ecnimede.  L.M.P.  received  personal  fees,  grants  and  non-
nancial  support  for  lectures  from  Bayer  and  Ferrer.  J.M.
eceived  personal  fees  for  consulting  services  and  lectures
rom  Bayer  Portugal,  AstraZeneca,  Servier,  Novartis,  Merck
41Amaral-Silva  et  al.
harp  &  Dhome,  Menarini  and  Amgen,  as  well  as  grants
or  scientific  research  from  Novartis,  Bristol  Myers  Squibb,
oehringer  Ingelheim  and  Ferrer.  M.T.V.  received  personal
ees  for  lectures  from  Tecnimede,  Meda  Pharma,  Merck
harp  &  Dhome,  Bayer  and  Amgen.  M.C.  declares  no  conflicts
f  interest.  J.C.,  J.A.,  R.A.,  M.F.C.,  F.L.,  A.V.C.  and  M.B.  are
embers  of  the  Evidence  Based  Medicine  Center  (CEMBE)  at
he  Faculty  of  Medicine,  University  of  Lisbon.  This  research
enter  is  devoted  to  pre-  and  postgraduate  medical  edu-
ation  and,  since  2002,  has  undertaken  several  clinical,
pidemiological  and  phamacoeconomic  research  projects,
hich  received  unrestricted  funding  from  over  20  different
harmaceutical  companies  including  Bayer  Portugal  SA.  F.F.
as  a  member  of  CEMBE  at  the  time  of  this  study.  M.G.
as  taken  part  in  several  research  projects  that  received
nrestricted  grants  from  pharmaceutical  companies  includ-
ng  Bayer  Portugal  SA.  None  of  the  authors  is  responsible  for
atents  relevant  for  this  work.
cknowledgments
e  are  grateful  to  the  ARSLVT  for  granting  access  to  infor-
ation  that  was  essential  to  this  study,  especially  data
xtracted  from  SIARS.
We  would  also  like  to  thank  the  Central  Administration
f  the  National  Health  System  (ACSS)  for  granting  access  to
he  BDMH.
ppendix A. Supplementary data
upplementary  material  related  to  this  article  can  be  found
n  the  online  version  at  doi:https://doi.org/10.1016/j.
epc.2020.08.007.
eferences
1. Mello e Silva AM. Atherosclerosis: Doença sistémica com
manifestações focais em territórios e manifestações clínicas.
Rev Factores Risco. 2007;6:40--5.
2. GBD 2017 Causes of Death Collaborators. Global, regional, and
national age-sex-specific mortality for 282 causes of death in
195 countries and territories, 1980--2017: a systematic anal-
ysis for the Global Burden of Disease Study 2017. Lancet.
2018;392:1736--88.
3. Wilkins E, Wilson L, Wickramasinghe K, et al. European
Cardiovascular Disease Statistics 2017. Brussels: European
Heart Network; 2017. Available at: http://www.ehnheart.org/
cvd-statistics/cvd-statistics-2017.html [Accessed 01 January
2019].
4. Instituto Nacional de Estatística IP (INE). Causas de
morte 2017. Available at: https://www.ine.pt/xportal/
xmain?xpid=INE&xpgid=ine publicacoes&PUBLICACOESpub boui
=358633033&PUBLICACOESmodo=2 [Accessed 01 January 2019].
5. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev
Dis Prim. 2019;5:56.
6. Instituto Nacional de Estatística IP (INE), Lisboa, Portugal
Inquérito Nacional de Saúde 2014; 2016.
7. Menezes J, Fernandes e Fernandes J, Carvalho C, et al. Estudo
da prevalência da doença arterial periférica em Portugal. Angiol
e Cir Vasc. 2009;5(2).
8. Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart























factors for coronary artery disease in primary health care in Por-Revista  Portuguesa  de  Ca
9. Gouveia MRde A, Ascenção RMSe S, Fiorentino F, et al. Os custos
da insuficiência cardíaca em Portugal e a sua evolução pre-
visível com o envelhecimento da população. Rev Port Cardiol.
2020;39:3--11.
0. Gouveia M, Ascenção R, Fiorentino F, et al. The current and
future burden of heart failure in Portugal. ESC Hear Fail.
2019;6:254--61, http://dx.doi.org/10.1002/ehf2.12399. Avail-
able at:.
1. Instituto Nacional de Estatística IP (INE). Portal do Instituto
Nacional de Estatística: População residente (N.o) por Local
de residência (NUTS -- 2013), Sexo e Grupo etário; Anual.
Lisboa. Instituto Nacional de Estatística; 2016. Available at:
https://www.ine.pt [Accessed 05 February 2018].
2. Administração Central do Sistema de Saúde IP (ACSS). Base de
dados de Morbilidade Hospitalar; 2016.
3. Agarwal S, Sud K, Shishehbor M. Nationwide trends of hospital
admission and outcomes among critical limb ischemia patients:
from 2003--2011. J Am Coll Cardiol. 2016;67:1901--13.
4. Vos T, Allen C, Arora M, et al. Global, regional, and national
incidence, prevalence, and years lived with disability for
310 diseases and injuries, 1990--2015: a systematic analy-
sis for the Global Burden of Disease Study 2015. Lancet.
2016;388:1545--602.
5. Barros PP. Políticas Públicas em Saúde: 2011--2014, Avaliação
do Impacto [Public Health Policies: 2011--2014. Impact Eval-
uation]. Lisboa: NOVA Healthcare Initiative -- Research 202.
Universidade Nova de Lisboa; 2015.
6. Administração Regional de Saúde de Lisboa e Vale do Tejo I.P.
(ARSLVT). Sistema de Informação da Administração Regional de
Saúde (SIARS); 2016. Accessed 2018.
7. Instituto Nacional de Estatística IP (INE). Estatísticas do
Emprego 2018 3.o trimestre. Lisboa: Instituto Nacional de
Estatística; 2018. Available at: http://www.ine.pt [Accessed 19
December 2018].
8. Becker G. Human Capital. New York: National Bureau of Eco-
nomic Research; 1975.
9. Gabinete de estratégia e planeamento. Ministério do Trabalho,
Solidariedade e Segurança Social. Boletim Estatístico - novem-
bro 2018; 2018.
41logia  40  (2021)  409--419
0. Justo A. Caraterização e Análise das Admissões Hospitalares
na Urgência do Centro Hospitalar Lisboa Central. Lisboa:
EPE; 2015. Available at: https://run.unl.pt/bitstream/103
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